Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GSK3174998 alone and with pembrolizumab in advanced solid tumors
NL-OMON47867Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of gsk3174998 and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 6 more (2 arms), sponsored by GSK. Primary endpoints: Safety and tolerability and Maximum tolerated dose or maximum administered dose. Started Sep 2015; status: active, not recruiting.
02
Drugs
gsk3174998pembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NL-OMON47867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47867.